Genentech, Inc.
About Genentech, Inc.
1697 articles about Genentech, Inc.
-
Genentech Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-Stage Small Cell Lung Cancer
3/30/2022
Genentech, a member of the Roche Group, announced that the Phase III SKYSCRAPER-02 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq® and chemotherapy as an initial treatment for people with extensive-stage small cell lung cancer, did not meet its co-primary endpoint of progression-free survival.
-
Interim data from Genentech’s first randomized study on a candidate treatment for extensive-stage small-cell lung cancer failed to meet its co-primary endpoint.
-
The study suggests that artificial sweeteners, which are readily available in coffee shops and used in diet soft drinks, increase the risks of breast cancer and obesity.
-
A federal judge in Delaware tossed out a lawsuit by Genentech, Inc., a Roche company, accusing Novartis' Sandoz division of patent infringement.
-
It was a busy week for clinical trial announcements. Here's a look.
-
A closer look at legal action against executives from the company formerly known as JHL Biotech who recruited scientists from Genentech to steal trade secrets related to several cancer drugs.
-
Genentech shared new data from its SUNFISH study evaluating the use of Evrysdi for SMA people ages 2 to 25 years diagnosed with Type 2 or Type 3 spinal muscular atrophy.
-
New Data for Genentech’s Evrysdi (risdiplam) Demonstrate Long-Term Efficacy and Safety in a Broad Population of People With Spinal Muscular Atrophy (SMA)
3/16/2022
Genentech, a member of the Roche Group, announced new data for Evrysdi® in spinal muscular atrophy.
-
Two former executives of JHL Biotech were sentenced to a year and one day each in prison after being found guilty of conspiracy and fraud.
-
Novartis released new data Monday from its Phase III SPR1NT trial that reinforces the benefits of Zolgensma.
-
Morningside Ventures launched a new biotech company called Adiso Therapeutics, and thriving startup Scenic Biotech scooped up €28 million ($31 million) in funding.
-
The clinical trial, called SKYLINE, is starting without results from other key ongoing studies on the drug.
-
CMS says it would only cover the cost of Biogen’s Aduhelm and any required scans “if they are enrolled in qualifying clinical trials.”
-
New Two-Year Data for Genentech’s Vabysmo and Susvimo Reinforce Potential to Maintain Vision With Fewer Treatments for People With Two Leading Causes of Vision Loss
2/11/2022
Genentech, a member of the Roche Group, announced that new two-year data from its Phase III studies of Vabysmo™ and Susvimo™ 100 mg/mL for intravitreal use via ocular implant will be presented at Angiogenesis, Exudation and Degeneration 2022 on Feb. 12.
-
New two-year data from Phase III studies of Susvimo and Vabysmo reinforce the two drugs' potential to improve the quality of life of patients diagnosed with DME and nAMD.
-
To address that lack of diversity, Medable and CVS have forged a collaboration to improve patient access to clinical trial research.
-
Clinical Trial Research at Wolfe Eye Clinic contributes to FDA Approval of Genentech's Vabysmo ™, the First Bispecific Antibody for the Eye, Treating Two Vision Loss Causes
2/3/2022
In a press release Friday, Genentech announced approval of Vabysmo™ (faricimab-svoa), a new advancement in the treatment approach for Wet Age-Related Macular Degeneration (AMD) and diabetic macular edema (DME).
-
Biogen announced it was exercising its option to participate in Genentech’s development of mosunetuzumab under a long-standing collaboration for antibodies targeting CD20.
-
The FDA's decision is based on positive results from several Phase III studies, including the TENAYA and LUCERNE clinical trials.
-
Clinical trial news definitely picked up this final week of January. Here’s a look.